Overview

Brain Small Chain Fatty Acid Metabolism in Parkinson Disease: Tributyrin Supplementation

Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
Small exploratory open-label pilot study to assess the short-chain fatty acid (SCFA) prodrug tributyrin as a potential therapy for persons with Parkinson disease
Phase:
Phase 1
Details
Lead Sponsor:
Nicolaas Bohnen, MD, PhD